From the middle of August through the end of September, the S&P 500 index tanked 16.6%, and the tech-heavy Nasdaq Composite index slid 19.4%. The Relief study showed that patients who started using Abbott's new CGM had 67% fewer hospitalizations for acute diabetic events after one year.